Few areas of medicine have attracted more controversy than prostate cancer screening (PSA) and early intervention in prostate cancer. Much of this followed two landmark trials (PLCO and ERSPC) that did not show a significant mortality benefit for PSA screening.
This content is restricted to site members. If you are an existing user, please log in. New users may register below.